Epsilon M&A Deal Report - Sanifit Therapeutics
Transaction Multiples for the Valuation of Private Companies
Vifor Pharma / Sanifit Therapeutics
No EMAT :
109063
Announced Date :
22/11/2021
Type :
Exit ,Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Vifor Pharma
Target :
Sanifit Therapeutics
Country :
Spain
Sector of activity :
- Health, Pharmaceuticals & Biotechnology > Biotechnology
Business Description :
Founded in 2007, Sanifit is a clinical-stage biotechnology company that develops treatments for patients with calcification disorders . > Focuses on treatments for end-stage kidney disease patients...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | ||||||||
| Current |
Rating :
**
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biotechnology » = 42
| Date | Acquirer | Target | Country | Multiples | See details |
| 22/11/2021 | Vifor Pharma | Inositec | Switzerland | *** | 109058 |
| 31/01/2022 | Private group led by Turenne Santé and BNP Paribas Développement | HAC Pharma | France | *** | 109042 |
Source: Epsilon Research / EMAT
